Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment
AssigneesInstitut Gustave Roussy, Universite Paris-Saclay, Institut National de la Sante et de la Recherche Medicale, Institut De La Recherche Agronomique
InventorsLaurence Zitvogel, Ivo Gomperts Boneca, Patricia Lepage, Sophie Viaud, Romain Daillere
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for determining if a patient is likely to benefit from a cancer treatment, by determining if said patient has a gut dysbiosis with an over representation of certain bacterial species. The present invention also provides probiotic strains to improve the efficacy of a cancer treatment, especially chemotherapy, in patients in need thereof.
Claims20
A method of treating cancer in a human subject in need thereof, comprising administering to the subject:
- (a) a probiotic composition comprising an amount of an Enterococcus hirae strain;
- and (b) dose(s) of an alkylating chemotherapeutic agent, wherein the administering of the probiotic composition and the alkylating chemotherapeutic agent to the subject induces a T-bet/Th1 local and systemic immune response, thereby treating the cancer in the subject.
A method of treating cancer in a human subject in need thereof, comprising administering to the subject:
- (a) a probiotic composition comprising an Enterococcus hirae strain;
- and (b) an alkylating chemotherapeutic agent, to thereby treat the cancer;
- wherein said Enterococcus hirae strain is one which mediates a TH1 and a pTH17 response in the spleen of C57BL/6 mice treated with broad-spectrum antibiotics for a period of 15 days, followed by administration of said alkylating chemotherapeutic agent in combination with oral gavage delivering 109 bacteria from of said Enterococcus hirae strain.
Dependencies are inferred from the claim text.